81 results about "DPP-4 Inhibitors" patented technology

The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and / or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and / or a non-oral antidiabetic drug.

The invention relates to antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia, inter alia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions. The medication is a mono treatment with a DPP-4 inhibitor <preferably linagliptin> or a combination treatment with a DPP-4 inhibitor and a second and / or third antidiabetic.

The present invention relates to methods for treating and / or preventing metabolic diseases comprising the combined administration of a DPP-4 inhibitor and a long-acting insulin. The invention further relates to a DPP-4 inhibitor for subcutaneous or transdermal use.

The present invention relates to methods for treating and / or preventing metabolic diseases comprising the subcutaneous or transdermal administration of a therapeutically effective amount of a certain DPP-4 inhibitor. The invention further relates to a subcutaneous combination of a certain DPP-4 inhibitor and GLP-1 having a short half life, particularly for reducing weight.

Disclosed are pharmaceutical compositions comprising fixed-dose combinations of an extended-release form of metformin, or a pharmaceutically acceptable salt thereof, coated with an immediate-release form of the DPP-4 inhibitor sitagliptin, or a pharmaceutically acceptable salt thereof.

The present invention relates to the use of a certain DPP-4 inhibitor for modifying food intake and regulating food preference.

The present invention relates to methods for treating and / or preventing metabolic diseases comprising the combined administration of a DPP-4 inhibitor and a long-acting insulin. The invention further relates to a DPP-4 inhibitor for subcutaneous or transdermal use.

The present invention relates to a certain DPP-4 inhibitor for use in cardio- and / or renoprotective therapy, including in patients at high vascular risk.

The present invention relates to methods for treating and / or preventing SIRS and / or sepsis comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and / or preventing a metabolic disease in a patient with or at risk of SIRS and / or sepsis.

Disclosed are pharmaceutical compositions comprising fixed-dose combinations of an extended-release form of metformin, or a pharmaceutically acceptable salt thereof, coated with an immediate-release form of the DPP-4 inhibitor sitagliptin, or a pharmaceutically acceptable salt thereof.

The present invention relates to methods for treating and / or preventing podocytes related disorders and / or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and / or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and / or nephrotic syndrome.

Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.

The present invention relates to solid forms of trelagliptin, a preparation method therefor and applications thereof, and relates specifically to six new solid forms of the dipeptidyl peptidase-4 inhibitor trelagliptin and preparation methods therefor, as well as to pharmaceutical compositions comprising said solid forms of trelagliptin, and uses of same in the preparation of medicines for the treatment of diseases mediated by dipeptidyl peptidase-4.

The present invention relates to the use of a combination of a certain DPP-4 inhibitor and an alpha-glucosidase inhibitor for use in therapy, e.g. for use in treating and / or preventing a metabolic disease such as type 2 diabetes mellitus and / or conditions related thereto. The invention also relates to the use of such combination for improving body weight control, reducing body weight, inducing satiety, inhibiting gastric emptying and / or reducing food intake, in a patient in need thereof.

Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.

A DPP-4 inhibitor comprising a peptide represented by the formula (1): Xe-Pro / Ala / Hyp-Xa-Xb-Xc-Xd (wherein Xe is an amino acid residue with an isoelectric point of 5.9 to 6.3; Pro / Ala / Hyp represents Pro, Ala, or Hyp; Xa is an amino acid residue other than Hyp, Pro, and Arg, or deletion; Xb is Gly, Pro, or deletion; Xc is Pro, Ala, or deletion; and Xd is an amino acid residue or deletion) as an active component. The inhibitor can be expected to bring out an effect of lowering blood glucose levels by enhancing effects of incretins; and the inhibitor may be used as a therapeutic agent for diabetes and, in addition, can act on the immune system or the like to be thus used in treatment for skin diseases or the like.

The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.

The invention provides a novel dipeptidyl peptidase IV (DPP-4) inhibitor type compound. The compound and optical isomers thereof, as well as pharmaceutically acceptable inorganic or organic salt can be used for treating diabetes, particularly non-insulin dependent diabetes and other diseases relevant to DPP-4. The definition of the substituent groups in the general formula (I) is the same as that in the specification.

The present invention relates to methods for treating and / or preventing podocytes related disorders and / or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and / or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and / or nephrotic syndrome.

The invention relates to a benzo-hexatomic ring derivative used as a DPP-4 inhibitor and application of the benzo-hexatomic ring derivative, in particular to compounds shown as in formula I, medicine compositions with the compounds shown as in the formula I and application of the compounds in preparing medicines for treating diseases related to DPP-4 or inhibiting the DPP-4.

The invention relates to an antidiabetic pharmaceutical composition, more specifically to a pharmaceutical composition containing a DPP-4 inhibitor and metformin hydrochloride and a preparation method thereof. The composition contains DPP-4 inhibitor and metformin hydrochloride two active components, and meglumine as the stabilizer. The pharmaceutical composition has excellent storage stability and excellent dissolution characteristics. The invention also provides a preparation method of the composition, the auxiliary materials of the preparation technology are easily available and low in price, thus being suitable for industrial production.

The present invention is directed to novel pharmaceutical compositions comprising fixed dose combinations of a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor), or a pharmaceutically acceptable salt thereof, and simvastatin, or pharmaceutically acceptable salt thereof, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes and hypercholesterolemia with such pharmaceutical compositions. In particular, the invention is directed to pharmaceutical compositions comprising fixed-dose combinations of sitagliptin phosphate and simvastatin.

The invention provides a drug for treating hepatocellular carcinoma. The drug comprises a glucagon-like peptide-1 receptor stimulant and / or a dipeptidyl peptidase 4 inhibitor. The invention further provides application of the glucagon-like peptide-1 receptor stimulant and / or dipeptidyl peptidase 4 inhibitor to preparation of a drug for preventing or treating hepatocellular carcinoma, to preparation of a drug for liver function recovery after liver transplantation, and to preparation of a drug for preventing liver cancer relapse after liver transplantation. The glucagon-like peptide-1 receptor stimulant and / or dipeptidyl peptidase 4 inhibitor generates a differential effect in a tissue specificity way, so as to inhibit cancer cell proliferation and promote cancer cell apoptosis, meanwhile, liver cells are protected against apoptosis, so that obesity-dependent liver cancer or non-dependent liver cancer can be treated or weakened.

Disclosed are pharmaceutical compositions comprising fixed-dose combinations of an extended-release form of metformin, or a pharmaceutically acceptable salt thereof, coated with an immediate-release form of the DPP-4 inhibitor sitagliptin, or a pharmaceutically acceptable salt thereof.

The invention relates to a reagent for detection of biological activity of glucagon-like peptide-1 (GLP-1). Each 100 microliters of the reagent mainly comprises 20 micrograms of a gene recombinant GLP-1 acceptor, a dipeptidyl peptidase-4 inhibitor of which the weight is 1% of the weight of a blood plasma sample, 480 micrograms of triphosadenine, 10 micrograms of guanosine triphosphate, 0.5 milligrams of 3-isobutyl-1-methylxanthine and 100 microliters of a membrane reaction solution. The GLP-1 acceptor is obtained by genetic recombination, is convenient for purification and reduces batch difference of the reagent. The GLP-1 acceptor is used as a probe for capturing GLP-1 so that detection sensitivity is improved, biological activity can be directly determined, sensitivity is high, and practicality is strong.

The invention belongs to the technical field of medicine preparation, and discloses a pharmaceutical composition containing a therapeutically effective amount of a glucagon-like peptide-1 (GLP-1) analogue and a dipeptidyl peptidase-4 (DPP-4) inhibitor and a preparation method thereof. The composition can effectively prevent, retard and treat type II diabetes, especially can effectively control the blood glucose concentration, and also can be used for treating diseases related to rising of the blood glucose concentration. In addition, the composition can reduce the use dosage of the GLP-1 analogue and the DPP-4 inhibitor, so as to effectively reduce side effects of the GLP-1 analogue and the DPP-4 inhibitor and improve the patient tolerance level.

The present invention relates to pharmaceutical compositions comprising a combination of a particular dipeptidyl peptidase-4 (DPP-4) inhibitor and an anti-hypertensive agent selected from the group consisting of an angiotensin II receptor antag-onist and an angiotensin converting enzyme inhibitor, kits containing such combinations and methods of using such compositions for the treatment of diabetes, diabetes-related disorders, hypertension, and hypertension-related disorders.

The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.

The invention relates to the related fields of immunology, pharmacy and medicine, discloses a method for preparing a hybridoma cell line and a monoclonal antibody based on B cell epitopes of dipeptidyl peptidase 4 (DPP-4) and an application thereof, and especially, relates to small molecular antigen peptides prepared by coupling the B epitopes of DPP-4 with intramolecular carrier peptides and quickly obtained by a synthetic method; the small molecular antigen peptides immunize mice to produce strong immune response, and can be used for preparing immune spleen lymphocytes and preparing hybrid tumor cells, antibodies and the like. The monoclonal antibody is secreted by the hybridoma cell line (having the preservation number of CCTCC No:C2017227), is a Th2 antibody, is IgG1 in the mice, inhibits the enzyme activity of DPP-4, is specifically combined with DPP-4, can develop a DPP-4 detection reagent and a DPP-4 inhibitor, can significantly reduce blood sugar, uric acid and four indexes ofcreatinine blood lipid, increases GLP-1, regulates oxidative stress and immune balance from Th1 trending to Th2, and reduces pancreatic inflammation; prepared drugs are used for preventing and treating diabetes and complications thereof, hyperuricemia, gout, kidney and liver diseases, hyperlipidemia, AS, cardiovascular diseases and Th1-related diseases.